We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Arterial Blood Liquid Biopsy Detects Circulating Melanoma Cells

By LabMedica International staff writers
Posted on 06 Oct 2015
Print article
Image: The CELLSEARCH semi-automatic system that can capture and quantify circulating tumor cells (Photo courtesy of Janssen Diagnostics).
Image: The CELLSEARCH semi-automatic system that can capture and quantify circulating tumor cells (Photo courtesy of Janssen Diagnostics).
Venous blood collection is simple and minimally invasive, and this approach has made circulating tumor cells (CTC) testing readily available to many cancer patients. The major drawback is the fact that CTCs are not always detectable for patients with clinically evident metastatic disease.

Currently, assays for CTCs have been approved for diagnostic purposes in metastatic breast, colorectal, or prostate cancer. In these diseases, the presence of CTCs in the peripheral blood is associated with decreased progression-free survival and decreased overall survival. The major challenge for this technology is that CTCs are not always found in the blood of patients with aggressive disease who would be expected to have high numbers.

Scientists at Thomas Jefferson University (Philadelphia, PA, USA) obtained blood specimens from both common femoral arteries and antecubital veins in 17 uveal melanoma patients with multiple hepatic metastases for CTC measurements. All patients had their primary uveal melanoma treated between 2000 and 2013. Ten patients had received radioactive plaque as their treatment for primary uveal melanoma and seven patients had enucleation of their affected eye. None of these patients had a local recurrence of primary uveal melanoma at the time of CTC measurement.

CTCs were analyzed using the standard CellSearch protocol and CellTracks Circulating Melanoma Cell Kit on the CellSearch System (Janssen Diagnostics, LLC, Raritan, NJ, USA). Cells expressing CD146 (Mel-CAM) were immunomagnetically enriched and stained with phycoerythrin (PE)-conjugated antibody specific to high molecular weight melanoma associated antigen (HMW-MAA), which is specific for melanoma cells. Samples were scanned on the CellTracks analyzer II fluorescent microscope (Veridex, LLC, Raritan, NJ, USA).

The investigators compared blood samples taken from uveal melanoma patients' veins compared to that collected from arteries, and found a much higher number of circulating tumor cells in blood collected from the arteries than in the veins. CTCs were detectable with greater frequency (100%) and in larger numbers (median 5, range 1 to 168) in all arterial blood specimens than in venous samples (52.9%; median 1, range 0 to 8). Patients with hepatic as well as extra-hepatic metastasis showed higher number of arterial CTCs, compared to patients with liver-only metastasis.

The authors concluded that their data indicated that arterial blood, rather than venous blood, might be suitable for future investigation on CTCs in uveal melanoma patients. This would also raise the concern as to whether venous blood specimens are a suitable source for investigation on CTCs in other types of cancer. Although it is more technically difficult to collect blood from an artery than a vein, this study suggests that checking arterial blood may be a more accurate way of assessing circulating tumor number, and therefore metastatic disease. The study was published on September 18, 2015, in the journal EBioMedicine.

Related Links:

Thomas Jefferson University
Janssen Diagnostics 
Veridex


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.